We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EMTK:IDXPT Elang Mahkota Teknologi Tbk Analysis

Data as of 2026-05-22 - not real-time

IDR 635.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

PT Elang Mahkota Teknologi’s stock is trading at IDR 635, well below its 20‑day (IDR 761.75), 50‑day (IDR 792.30) and 200‑day (IDR 1,048.68) moving averages, signaling a strong bearish technical backdrop. The RSI of 23 indicates the shares are oversold, yet the MACD remains in a bearish configuration with the line below the signal, and volume has been decreasing, reinforcing downside pressure. Volatility is elevated at roughly 47% over the past 30 days, though the beta is low, suggesting limited systematic market risk. On the fundamentals side, revenue surged 47.6% year‑on‑year and profit margins sit at a respectable 13.4%, but the company carries a high debt‑to‑equity ratio of 4.5 and posted negative free cash flow, raising concerns about financial stability. The trailing P/E of 13.8 looks reasonable, but a forward P/E of 96.6 reflects a sharp earnings outlook decline, while the DCF‑derived fair value of about IDR 1,249 points to a substantial intrinsic undervaluation.
The recent announcement that EMTK will not distribute dividends for FY2025 undermines the attractiveness of its historically high 5.7% yield and questions dividend sustainability. Given the blend of strong top‑line growth, significant leverage, and a pending dividend cut, short‑term pressure is likely to persist, but the sizable gap between market price and intrinsic value could present a longer‑term buying opportunity if the company can improve cash generation and reduce debt.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below all major moving averages
  • Bearish MACD and decreasing volume
  • Dividend suspension reducing near‑term yield

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Robust revenue growth and solid profit margins
  • Significant intrinsic undervaluation versus market price
  • High leverage and negative free cash flow limiting upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value suggests large upside potential
  • Diversified business segments (media, digital, healthcare, aviation)
  • Opportunity to improve capital structure and restore dividend

Key Metrics & Analysis

Financial Health

Revenue Growth47.60%
Profit Margin13.43%
P/E Ratio13.8
ROE9.00%
ROA1.19%
Debt/Equity4.51
P/B Ratio1.1
Op. Cash FlowIDR2101.4B
Free Cash FlowIDR-287386501120
Industry P/E17.1

Technical Analysis

TrendBearish
RSI23.2
SupportIDR 635.00
ResistanceIDR 890.00
MA 20IDR 761.75
MA 50IDR 792.30
MA 200IDR 1,048.68
MACDBearish
VolumeDecreasing
Fear & Greed Index91.5

Valuation

Fair ValueIDR 1,248.65
GradeUndervalued
TypeBlend
Dividend Yield5.67%

Risk Assessment

Beta0.18
Volatility47.41%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.